United Therapeutics Corporation
Tyvaso
idiopathic pulmonary fibrosis
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on Tyvaso for idiopathic pulmonary fibrosis is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“United Therapeutics plans to seek priority review of a supplemental New Drug Application, to be submitted to the U.S. Food and Drug Administration (FDA) by the end of this summer, to add IPF to the labeled indications for nebulized Tyvaso b”